#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
# Clinical Summary The expiration of medicinal cannabis grandfathering arrangements in regulated jurisdictions now requires in-person consultations for most patients continuing or initiating cannabis-based treatments, a change that affects clinical workflow and patient access patterns. Previously, some jurisdictions allowed remote consultations or exemptions for established patients, but regulatory bodies are tightening requirements to ensure proper clinical assessment, drug interaction screening, and documentation of medical necessity. This shift increases the administrative burden on both prescribers and patients while potentially improving the quality of cannabis medicine practice through standardized clinical evaluation. Clinicians should anticipate increased appointment demand and clarify their jurisdiction’s specific consultation requirements, particularly for renewals versus new prescriptions. Patients on established cannabis regimens may face disruption if they previously relied on remote consultations, necessitating advance scheduling and travel logistics. Clinicians should proactively communicate these regulatory changes to their cannabis patients and update their practice protocols to maintain continuity of care during this transition period.
💊 The transition away from grandfathering arrangements for medicinal cannabis prescribing represents a significant shift toward standardized clinical governance, requiring providers to reassess their current prescribing practices and patient relationships. While the move toward in-person consultations in specific circumstances aims to ensure appropriate oversight and reduce potential misuse, clinicians should recognize that this policy change may create workflow disruptions and access barriers, particularly for patients with stable, long-established cannabis regimens who may face unnecessary reassessment. The complexity lies in balancing regulatory compliance with clinical continuity and patient burden, especially given the limited robust evidence base for many cannabis indications and heterogeneous patient populations. Providers should proactively review their patient roster to identify those affected, document clinical rationale for current prescriptions thoroughly, and prepare patients for potential consultation requirements or transitions in their care pathway to minimize disruption to therapeutic relationships and treatment efficacy.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
